Christopher D. Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher D. Miller has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Ben W. Lomaestro
Department of Pharmacy, Albany Medical Center Hospital
1 shared publicationDavid S. Perlin
Albany, New York; and Public Research Institute, Newark, New Jersey
1 shared publicationJohn J. Faragon
Division of HIV Medicine, Albany Medical College, Albany, New York
1 shared publicationRamy El‐Kholi
Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York
1 shared publicationSteven Park
Albany, New York; and Public Research Institute, Newark, New Jersey
1 shared publicationThomas P. Lodise
Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York
1 shared publication
Latest Publications
- 1 October 2007
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (10) , 1379-1386
Prevalence and Risk Factors for Clinically Significant Drug Interactions with Antiretroviral Therapy
Study Objectives. To identify the prevalence and types of clinically significant drug interactions (CSDIs) in the drug regimens of patients with human immunodeficiency virus (HIV) infection who were receiving antiretroviral therapy and to explore risk factors for these CSDIs.Design. Retrospective medical record review.Setting. Academic HIV specialty clinic.Patients. One hundred fifty‐three randomly selected patients with HIV infection who were receiving antiretroviral therapy from May 1‐September 30, 2006.Measurements and Main Results. Data were collected on patient demographics, date of HIV diagnosis, most recent viral load and CD4+ count, Centers for Disease Control and Prevention HIV classification, and comorbid conditions. Patients' drug regimens were analyzed for total and clinically significant antiretroviral drug interactions using three resources. Logistic regression and classification and regression tree analysis were used to identify independent CSDI predictors. Clinically significant drug interactions were defined as drug interactions that required a dosage adjustment or consisted of a drug combination that is contraindicated due to its high potential for clinical adverse effects. Of the 153 patients, at least one CSDI was found in 41.2% of their regimens: 34.6% with at least one drug interaction that required a dosage adjustment, 2.0% with at least one contraindicated drug combination, and 4.6% with at least one of each of these CSDIs. In the logistic regression model, risk factors independently associated with CSDIs were age older than 42 years (odds ratio [OR] 2.9, 95% CI 1.2–7.1), more than three comorbid conditions (OR 3.0, 95% CI 1.4–6.6), treatment with more than three antiretroviral agents (OR 2.4, 95% CI 1.0–5.8), and treatment with a protease inhibitor (OR 11.5, 95% CI 4.2–31.2). When directly compared, CSDIs were more prevalent among protease inhibitor–based than nonnucleoside reverse transcriptase inhibitor–based regimens (pConclusion. Clinically significant drug interactions are highly prevalent among HIV‐infected patients receiving antiretroviral therapy. Knowledge of the risk factors for CSDIs may help clinicians recognize and manage CSDIs.
- 1 October 2007
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (10) , 1379-1386
Prevalence and Risk Factors for Clinically Significant Drug Interactions with Antiretroviral Therapy
Study Objectives. To identify the prevalence and types of clinically significant drug interactions (CSDIs) in the drug regimens of patients with human immunodeficiency virus (HIV) infection who were receiving antiretroviral therapy and to explore risk factors for these CSDIs.Design. Retrospective medical record review.Setting. Academic HIV specialty clinic.Patients. One hundred fifty‐three randomly selected patients with HIV infection who were receiving antiretroviral therapy from May 1‐September 30, 2006.Measurements and Main Results. Data were collected on patient demographics, date of HIV diagnosis, most recent viral load and CD4+ count, Centers for Disease Control and Prevention HIV classification, and comorbid conditions. Patients' drug regimens were analyzed for total and clinically significant antiretroviral drug interactions using three resources. Logistic regression and classification and regression tree analysis were used to identify independent CSDI predictors. Clinically significant drug interactions were defined as drug interactions that required a dosage adjustment or consisted of a drug combination that is contraindicated due to its high potential for clinical adverse effects. Of the 153 patients, at least one CSDI was found in 41.2% of their regimens: 34.6% with at least one drug interaction that required a dosage adjustment, 2.0% with at least one contraindicated drug combination, and 4.6% with at least one of each of these CSDIs. In the logistic regression model, risk factors independently associated with CSDIs were age older than 42 years (odds ratio [OR] 2.9, 95% CI 1.2–7.1), more than three comorbid conditions (OR 3.0, 95% CI 1.4–6.6), treatment with more than three antiretroviral agents (OR 2.4, 95% CI 1.0–5.8), and treatment with a protease inhibitor (OR 11.5, 95% CI 4.2–31.2). When directly compared, CSDIs were more prevalent among protease inhibitor–based than nonnucleoside reverse transcriptase inhibitor–based regimens (pConclusion. Clinically significant drug interactions are highly prevalent among HIV‐infected patients receiving antiretroviral therapy. Knowledge of the risk factors for CSDIs may help clinicians recognize and manage CSDIs.
- 1 June 2006
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (6) , 877-880
Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin
Candida esophagitis, a defining illness of acquired immunodeficiency syndrome (AIDS), requires systemic antifungal therapy. Candida albicans can become resistant to commonly administered azole antifungal agents. An attractive alternative is caspofungin, an echinocandin antifungal that has generally displayed predictable activity against C. albicans. We report the case of a 29‐year‐old woman with AIDS who developed recurrent esophagitis caused by a strain of C. albicans that showed reduced susceptibility to caspofungin (elevated minimum inhibitory concentration of 8 mg/L). Analysis of the strain revealed that it contained a serine‐to‐proline substitution at position 645 in the FKS1 gene. Clinicians who prescribe caspofungin to treat esophagitis caused by C. albicans should recognize the potential risk, albeit slight, for acquired resistance to caspofungin and possibly other echinocandin antifungal agents in the face of persistent disease. In patients who are refractory or unresponsive to caspofungin therapy, susceptibility testing and/or alternative therapy should be considered.
- 1 June 2006
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (6) , 877-880
Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin
Candida esophagitis, a defining illness of acquired immunodeficiency syndrome (AIDS), requires systemic antifungal therapy. Candida albicans can become resistant to commonly administered azole antifungal agents. An attractive alternative is caspofungin, an echinocandin antifungal that has generally displayed predictable activity against C. albicans. We report the case of a 29‐year‐old woman with AIDS who developed recurrent esophagitis caused by a strain of C. albicans that showed reduced susceptibility to caspofungin (elevated minimum inhibitory concentration of 8 mg/L). Analysis of the strain revealed that it contained a serine‐to‐proline substitution at position 645 in the FKS1 gene. Clinicians who prescribe caspofungin to treat esophagitis caused by C. albicans should recognize the potential risk, albeit slight, for acquired resistance to caspofungin and possibly other echinocandin antifungal agents in the face of persistent disease. In patients who are refractory or unresponsive to caspofungin therapy, susceptibility testing and/or alternative therapy should be considered.